Peptides
78 peptides with dosing protocols, research, and safety data.
Adipotide
Adipotide is a targeted peptidomimetic agent designed to induce fat loss by selectively disrupting the vasculature of white adipose tissue. It functions by binding to prohibitin receptors on blood vessels supplying fat cells, triggering apoptosis and subsequent fat mass reduction. In preclinical trials, it has demonstrated significant reductions in body weight and improvements in insulin sensitivity. Due to its pro-apoptotic mechanism and potential renal toxicity, Adipotide is typically used in short-term cycles under clinical supervision.
Standard dose: 3 mg/kg SubQ daily for 2β4 weeks.
5-Amino-1MQ
5-Amino-1MQ is a lipophilic small molecule that inhibits the enzyme NNMT, enhancing energy metabolism and promoting fat loss while preserving lean muscle. Preclinical studies show notable effects on adipose tissue, cholesterol reduction, and enhanced mitochondrial function. It is being explored in preclinical models for potential fat loss and metabolic modulation.
Typical dose: 50β150 mg orally daily with food for 20β30 days, followed by 1β2 weeks off.
AICAR
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a nucleotide analog and AMPK agonist that mimics cellular energy stress, leading to enhanced fat oxidation, glucose uptake, and endurance capacity. It has been studied in metabolic and athletic contexts for its ability to trigger exercise-like effects without physical activity. AICAR is also used experimentally for improving mitochondrial function and insulin sensitivity. Best suited for short-term cycles with careful monitoring to avoid over-activation of AMPK. All data is based on animal or cellular models.
Standard dose: 50 mg/kg IV once daily, typically pre-exercise or in morning.
Seractide/ACTH (1-39)
ACTH (1-39), also known as Seractide, is a full-length synthetic form of adrenocorticotropic hormone used to evaluate adrenal function in diagnostic testing. It mimics natural ACTH, triggering cortisol release from the adrenal cortex in response to hypothalamic or pituitary dysfunction.
0.25 mg IM or IV as a single dose for adrenal stimulation testing. Monitor cortisol response within 30β60 minutes.
AOD-9604
AOD-9604 is a modified peptide fragment of human growth hormone designed to stimulate fat metabolism while avoiding the adverse effects associated with hGH therapy. It promotes lipolysis, inhibits fat formation, and has a proven safety profile in human studies. It has been explored in clinical research for obesity and metabolic modulation.
500 mcg SubQ daily or 1 mg oral troche, taken in the morning on an empty stomach for 8β12 week cycles.
Cagrilintide
Cagrilintide is a novel, long-acting amylin analogue developed for weight loss and metabolic support. It works by mimicking the hormone amylin, enhancing satiety and reducing caloric intake. Clinical trials have demonstrated robust weight reduction, especially when co-administered with semaglutide. Still investigational, it shows promise in future obesity pharmacotherapy pipelines. It is often combined with GLP-1 agonists in research settings for additive effects on satiety
Start at 0.25 mg SQ weekly, titrate to 1.2 mg β 2.4 mg β 4.5 mg based on tolerance. Standard maintenance: 2.4 mg weekly. Phase 3 trials tested up to 4.5 mg for advanced weight management. Often paired with semaglutide (CagriSema protocol).
BPC-157
BPC-157 is a synthetic peptide derived from a sequence found in human gastric juice. It has been extensively studied in rodent models for its effects on healing, angiogenesis, and inflammation reduction. Though widely researched, it is not approved for human or veterinary use.
Standard dose: 500 mcg SubQ or 1 mg orally, administered daily.
Argipressin
Argipressin (vasopressin) is a synthetic analog of antidiuretic hormone used in acute care to manage hypotension in vasodilatory shock and control excessive diuresis in diabetes insipidus. It acts on V1 and V2 receptors to regulate vascular tone and water reabsorption in the kidneys.
Typical infusion dose: 0.01β0.04 units/min IV titrated based on clinical response.
ARA-290
ARA-290 is a non-erythropoietic peptide derived from erythropoietin that targets the innate repair receptor (IRR) to reduce inflammation and promote healing, particularly in neuropathic pain, cardiovascular inflammation, and microvascular dysfunction. It avoids stimulating red blood cell production, making it safer for chronic therapeutic use.
Standard dose: 4 mcg/kg SubQ daily for 4 weeks.
Cetrorelix
Cetrorelix is a synthetic GnRH antagonist used to suppress LH and FSH secretion during controlled ovarian stimulation in IVF. It enables precise timing of ovulation and prevents premature hormonal surges that can compromise reproductive outcomes.
Daily protocol: 0.25 mg SQ once daily starting day 5β6 of ovarian stimulation for 5β10 days. Single-dose protocol: 3 mg SQ once on stimulation day 7 (lasts ~4 days, no daily injections needed). Both protocols used in ART under strict monitoring.
Cartalax
Cartalax is a synthetic short peptide bioregulator derived from cartilage tissue. It supports regeneration of the extracellular cartilage matrix, stimulates fibroblast and chondrocyte activity, and may alleviate symptoms of osteoarthritis and other degenerative joint diseases. Commonly used in short injectable cycles with minimal systemic side effects.
Standard dose: 4 mg SQ daily for 10β20 days. Range: 2β6 mg daily. Repeat cycles every 3β6 months for chronic joint health. Some protocols split into 2β3 smaller daily doses.
Cardiogen
Cardiogen is a synthetic peptide shown to enhance cardiac regeneration, vascular perfusion, and myocardial bioenergetics. Originally developed to support heart recovery post-infarction, it is now studied for broader cardiometabolic and vascular applications in aging and disease. It acts by modulating endothelial and cardiac signaling at the cellular level.
100 mcg/kg SubQ daily or 100 mcg IM weekly for 8 weeks, followed by reassessment.
Cortexin
Cortexin is a peptide-based neurobioregulator derived from bovine brain extracts, widely used in Eastern Europe for cognitive decline, stroke recovery, and neurodevelopmental disorders. It exerts neuroprotective, metabolic, and anti-inflammatory effects, enhancing memory, learning, and synaptic repair.
Standard dose: 10 mg IM daily for 10 days; repeat cycle every 3β6 months as needed.
Cortagen
Cortagen is a short synthetic tetrapeptide that exhibits neuroprotective and regenerative effects, particularly after injury. It has been shown to support cognitive function, nerve regrowth, and cardiovascular recovery. Used in protocols for TBI, aging, ischemia, and inflammatory neurodegeneration.
0.1 mg/kg SubQ once daily for 10β20 days per cycle. Repeatable 2β4x yearly depending on goal.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed with a longer half-life to support prolonged GH secretion in research settings. It is studied for its pharmacokinetic improvements over natural GHRH, especially when combined with GHRP peptides. The DAC modification allows for extended half-life and reduced injection frequency while significantly elevating IGF-1 levels.
Standard dose (no DAC / Mod GRF 1-29): 100 mcg SQ per injection, 2β3x daily. Best timing: 30 min before meals or at bedtime. Common protocol: 5 days on, 2 days off in 8β12 week cycles. Often combined with a GHRP (Ipamorelin, GHRP-2, or GHRP-6) for synergistic GH release.
DSIP (Delta Sleep-Inducing Peptide)
DSIP (Delta Sleep-Inducing Peptide) is a short neuropeptide with documented ability to promote deep sleep, reduce stress, and modulate circadian rhythms. Often used to support recovery, anxiety reduction, and HPA balance, DSIP has broad experimental interest for its neuroendocrine effects.
200 mcg SubQ 30β60 minutes before sleep. Use for 2β4 weeks per cycle.
Dihexa
Dihexa is a synthetic neurogenic peptide that enhances cognitive performance and brain plasticity through HGF/c-Met activation. It promotes memory formation, synaptic repair, and long-term potentiation, and is under investigation for Alzheimer's, stroke recovery, and neurodegeneration.
5 mg oral daily or 1% topical cream applied 1β2x daily for 8β12 weeks.
Crystagen
Crystagen is a thymic-derived peptide bioregulator that modulates immune function, supports thymic repair, and enhances lymphocyte output. It is administered orally and has been shown in Eastern European research to improve immune performance in aging and immunosuppressed individuals.
1β2 capsules daily for 10β30 days depending on immune status. Repeat 2β3x per year.
Exenatide
Exenatide is a GLP-1 receptor agonist approved for type 2 diabetes treatment. It mimics incretin hormones to stimulate insulin secretion in a glucose-dependent manner, suppresses glucagon, delays gastric emptying, and aids in weight reduction. Available in twice-daily and weekly extended-release formulations, it also shows potential benefits in hepatic fat reduction and neuroprotection.
Start with 5 mcg SubQ twice daily before meals; increase to 10 mcg if tolerated. For extended-release, 2 mg once weekly.
N-Acetyl Epithalon Amidate
N-Acetyl Epithalon Amidate is a bioavailable synthetic peptide analog of Epitalon designed to support DNA repair, telomere lengthening, and pineal regulation. It may improve sleep, boost cognitive performance, and delay signs of biological aging through epigenetic and circadian mechanisms in animal models.
Standard dose: 300 mcg SQ daily for 8β10 weeks per cycle. Range: 100β1000 mcg daily depending on protocol. Repeat 1β2x per year for longevity and telomere support.
Elamipretide
Elamipretide is a mitochondria-targeted tetrapeptide developed to support mitochondrial health and energy production. It binds cardiolipin in the inner mitochondrial membrane, preserving mitochondrial structure and reducing oxidative stress. Elamipretide has shown benefit in patients with primary mitochondrial myopathies, cardiovascular disease, and other conditions associated with impaired energy metabolism. It is commonly used in protocols that involve SS-31 or serve as follow-up to NAD+ and MOTS-c-based mitochondrial repair stacks.
FDA-approved dose (Stegazo): 40 mg SQ once daily for patients β₯40 kg. For Barth syndrome, clinical trials used 40 mg/day subcutaneously for 12-week cycles.
FOXO4-DRI
FOXO4-DRI is a synthetic senolytic peptide that promotes apoptosis of senescent cells by disrupting the FOXO4-p53 interaction. It has demonstrated anti-aging potential by improving tissue function, reducing inflammation, and restoring youthful cellular profiles in preclinical aging models.
2 mg/kg SubQ once daily for 3β5 consecutive days per cycle. Repeat every 3β6 months for senolytic maintenance.
Follistatin 344
Follistatin 344 (FS344) is a potent myostatin inhibitor that promotes muscle hypertrophy and strength by suppressing GDF-8 and activin pathways. It is explored in gene and peptide therapies for muscle-wasting diseases and performance enhancement. Human safety and regulatory pathways are still under evaluation.
1 mg/kg SubQ once weekly for 4β6 weeks. Some protocols use 1β2 mg SubQ every 3β4 days depending on muscle gain goals.
FGL
FGL (FG loop peptide) is a synthetic neuropeptide derived from NCAM sequences that promotes neural repair, neurotrophin signaling, and memory formation. It enhances learning via FGFR1 activation and is under investigation for cognitive impairment, Alzheimerβs, and ischemia recovery. Delivered intranasally, it bypasses the BBB and targets brain-specific pathways.
400 mcg intranasally 3β5x per week. Suggested cycle duration: 6β12 weeks.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide known for its regenerative and anti-aging effects. It promotes collagen production, speeds wound healing, improves skin texture, and supports hair follicle health. Widely used in cosmetic serums and creams for skin rejuvenation and hair growth in vitro and in vivo.
Apply 1% topical solution once or twice daily to skin or scalp for 4β12 weeks. Maintenance use is safe long-term.
GDF-8 (Myostatin Inhibitor)
GDF-8, also known as Myostatin, is a negative regulator of muscle growth. Inhibiting GDF-8 through peptide analogs or propeptides has shown promise in increasing muscle mass and preventing muscle wasting in conditions like muscular dystrophy and cachexia. Though animal studies are promising, translation to human therapies has been limited by safety and delivery challenges.
Typical dosing ranges from 50β200 mcg SubQ 1β2x weekly for 6β12 week cycles. Clinical protocol still experimental.
Frag 176-191
Frag 176-191 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). It has been studied in preclinical models for its ability to modulate fat metabolism without the insulin or IGF-1 signaling typically associated with full-length hGH. It is not considered anabolic but is of interest for its targeted lipolytic properties in laboratory research.
500 mcg SubQ 1β2x daily (preferably fasted in AM and/or pre-bed). Cycle for 4β8 weeks.
Gonadorelin
Gonadorelin is a synthetic gonadotropin-releasing hormone (GnRH) used for diagnostic and therapeutic purposes in reproductive and endocrine medicine. It stimulates the anterior pituitary to release LH and FSH and is used in fertility restoration, hormone replacement, and hypothalamic amenorrhea treatment.
Standard diagnostic dose: 0.1 mg IV as a single bolus. Therapeutic pulsatile use: 5β20 mcg IV or SubQ every 90β120 minutes for HRT or fertility.
GHRP-6
GHRP-6 is a growth hormone-releasing hexapeptide that mimics ghrelin to stimulate the pituitary gland. It is studied in both preclinical and clinical settings for its GH-promoting and appetite-stimulating properties; commonly stacked with CJC-1295 for synergistic GH release.
200 mcg SubQ 1β2x daily, or 30 mcg intranasal 1β2x daily. Best used in 8β12 week cycles.
GHRP-2
GHRP-2 is a potent growth hormone secretagogue that stimulates the natural release of GH via the ghrelin receptor. It has been evaluated in preclinical and limited human research for its endocrine and appetite-regulating effects. It supports GH-IGF-1 axis activation with minimal prolactin or cortisol impact at moderate doses.
Standard dose: 100β300 mcg SQ 1β2x daily. Best administered 30 min before meals or at bedtime to coincide with natural GH pulse patterns. Use in 6β12 week cycles, followed by 2β4 week break to reset receptor sensitivity. Often stacked with CJC-1295 (no DAC) or GHRP-6.
IGF-1 DES
IGF-1 DES is a truncated, highly active form of IGF-1 with enhanced potency at muscle sites due to its low affinity for IGFBPs. It is studied for its potent anabolic signaling in muscle cells, especially during acute injury or mechanical overload in preclinical models.
50 mcg/kg SubQ daily post-workout or at localized injury sites for 4β6 weeks.
Humanin
Humanin is a mitochondrial-derived peptide (MDP) with potent cytoprotective and neuroprotective functions. It interacts with IGFBP-3 and activates AMPK, PI3K/Akt, STAT3, and FOXO pathways to enhance mitochondrial metabolism, reduce apoptosis, and combat oxidative stress. Humanin shows promise in aging-related conditions, including Alzheimer's, cardiovascular disease, and metabolic dysfunction. It is used in longevity protocols to support brain function, mitochondrial stability, and glucose regulation in both in vitro and rodent models.
Standard dose: 1 mg SubQ daily for 4β6 weeks.
Hexarelin
Hexarelin is a potent growth hormone secretagogue peptide that stimulates GH release via ghrelin receptor binding. It is studied in animal models and human research for its robust GH stimulation and potential cardiovascular effects. Although effective, long-term continuous use may lead to GH axis desensitization.
Standard dose: 1 mcg/kg SQ daily (typically ~50β100 mcg for most adults). Literature: 100 mcg SQ 1β2x daily in limited human studies. Protocol: 5 days on, 2 days off or daily for 8β12 weeks with equal time off to prevent GH receptor desensitization.
Kisspeptin-10
Kisspeptin-10 is a potent regulator of reproductive hormone signaling that stimulates GnRH secretion from the hypothalamus, which in turn increases LH and FSH levels to support testosterone, estrogen, and fertility. It has been studied for its role in treating hypogonadism, improving libido, and optimizing reproductive cycles. Emerging research also suggests metabolic benefits through its effects on insulin sensitivity and fat regulation.
Clinical research doses: 1β10 mcg/kg IV or SQ as single bolus. Diagnostic use: 1 mcg/kg IV to assess gonadotropin response. Therapeutic research: 4β10 mcg/kg SQ daily for 2β4 weeks in reproductive endocrine studies. Monitor LH, FSH, testosterone, and estrogen.
Ipamorelin
Ipamorelin is a highly selective GHRP with minimal side effects compared to earlier growth hormone secretagogues. It boosts natural GH secretion while avoiding significant stimulation of cortisol or prolactin. It has been investigated in both in vitro models and animal research for anti-aging, muscle recovery, and fat-loss protocols.
Standard dose: 200 mcg SQ at bedtime or 200β300 mcg up to 3x/day. Protocol: 5 nights on, 2 nights off, in 8β12 week cycles followed by equal off time. Often combined with CJC-1295 (no DAC) for synergistic GH release.
NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme involved in redox reactions, DNA repair, and energy metabolism. NAD+ precursors and NAD+ IV/IM formulations are studied for their effects on aging, mitochondrial health, and cellular stress.
Standard dose: 500 mg Oral daily; 500 mg IV once weekly; 50 mg SubQ 1β3x weekly
LL-37
LL-37 is a naturally occurring antimicrobial peptide in the cathelicidin family, integral to innate immune defense. It exerts antimicrobial, immunomodulatory, and wound-healing effects through membrane disruption, immune activation, and epithelial regeneration. Its applications span infectious disease, chronic wounds, and immune regulation.
200 mcg SubQ daily or topical application 1β2x daily to affected site. Research-based; clinical protocols still under development.
Livagen
Livagen is a thymic-derived short peptide with powerful gene-regulatory effects. It stabilizes chromatin, promotes DNA repair, and enhances immune signaling, particularly in aging individuals. It is studied for its epigenetic role in longevity and tissue regeneration.
10 mcg/kg SubQ daily for 20β30 days. Repeat 1β2x per year for aging and immune support.
KPV
KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH with strong anti-inflammatory, antimicrobial, and antifungal properties. It is being explored for use in inflammatory bowel diseases, topical inflammatory skin conditions, and systemic inflammation. Multiple delivery routes have been studied, including oral, SubQ, and topical forms.
250β500 mcg oral or SubQ daily. Topical: 2% KPV cream applied twice daily to affected areas.
Melanotan II
Melanotan II is a synthetic melanocortin peptide that increases melanin production and stimulates sexual arousal. It binds MC1R for tanning and MC4R for libido enhancement, and has been studied for its effects on skin pigmentation and sexual arousal in preclinical models and limited human trials. Unlike MT-1, it has central nervous system activity.
0.5 mg SubQ as needed. Titrate up from 0.25 mg to assess sensitivity. Cycle 10β14 days for tanning, then reduce to 1β2x/week.
Melanotan I
Melanotan I (afamelanotide) is a synthetic alpha-MSH analog used to increase melanin production and reduce UV sensitivity. Approved for photoprotection in EPP, it provides a cosmetic tanning effect and may offer broader applications for sunburn prevention and skin tone enhancement.
0.5 mg SubQ daily for 10β14 days. Maintenance: 1β2x per week thereafter.
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist developed for obesity and metabolic disorders. It improves glucose metabolism, increases satiety, reduces food intake, and promotes significant weight loss. Clinical studies have shown strong efficacy in reducing body weight and visceral fat, with ongoing trials exploring long-term cardiovascular and endocrine benefits. Developed by Innovent Biologics, it has shown promising results in early clinical trials in China
Start at 2 mg SQ weekly for 2β4 weeks, then titrate to 4 mg β 6 mg β 9 mg based on GI tolerance. Standard maintenance: 6 mg weekly. Clinical trials tested up to 9 mg weekly for advanced weight management. Monitor glucose, lipids, renal function, and thyroid markers.
MOTS-c
MOTS-c is a mitochondrial-derived peptide with potential therapeutic applications in metabolic and age-related diseases. It is involved in metabolic regulation, showing promise in conditions like insulin resistance and obesity. It has been evaluated in rodent models and cell culture for potential applications in aging and metabolic disorders.
Standard dose: 10 mg subcutaneous injection, 3 times per week.
MK-677 (Ibutamoren)
MK-677 (Ibutamoren) is a long-acting, orally active ghrelin mimetic that stimulates the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) by binding to the GHS-R1a receptor. It has been studied in preclinical and clinical research for its potential to support GH/IGF-1 axis signaling, muscle mass retention, and metabolic regulation in aging and disease models.
20 mg oral daily, typically taken before bed for optimal GH and sleep effects. Cycle 8β12 weeks with optional breaks.
MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is an IGF-1 splice variant upregulated in muscle post-injury or resistance training. It activates muscle satellite cells, facilitating localized tissue repair and hypertrophy. PEGylated forms are used to extend its half-life and improve delivery. It has been studied in vitro and in animal models for its role in muscle regeneration and tissue growth signaling.
200β400 mcg SubQ or IM, 2β3x weekly post-workout. Cycle length: 6β12 weeks with time off.
Ovagen
Ovagen is a liver-specific peptide bioregulator derived from organ peptides and studied for hepatic regeneration, enzyme stabilization, and oxidative protection. It may aid in liver recovery following toxic damage, viral infection, or age-related liver decline.
2 mcg/kg SubQ daily for 20β30 days. Cycles may be repeated 2β3 times per year depending on liver function.
Orexin A
Orexin A is a wake-promoting neuropeptide that modulates sleep, alertness, appetite, and cognitive function. It acts on orexin receptors in the brain and is being researched as a treatment for narcolepsy, fatigue, and age-related cognitive decline. Intranasal delivery allows fast CNS uptake for energizing and neurostimulant effects.
2.5 mg intranasally once daily in the morning or as needed. Adjust based on arousal and tolerance.
PACAP
PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) is a neuroprotective peptide with potent effects on neuron survival, cognition, and inflammation regulation. It has shown promise in models of Alzheimerβs, stroke, and cognitive decline, while also being studied for its role in migraine physiology.
200 mcg intranasal 3β5x/week for up to 12 weeks. Adjust based on cognitive, migraine, or neuroprotective outcomes.
P21
P21 is an investigational tumor-targeting peptide under preclinical development for oncology and neurotherapeutics. It acts by penetrating cancer cells via CXCR4 or similar receptors and may disrupt mitochondrial energy production. It is also being evaluated for cell-penetrant cargo delivery and cognitive enhancement.
No standard clinical dose established. Protocols vary across preclinical and investigational uses.
Oxytocin
Oxytocin is a nonapeptide hormone that promotes uterine contraction, lactation, and emotional bonding. Intranasal oxytocin is under investigation for its effects on social cognition, emotional regulation, and conditions like autism and anxiety. It modulates brain circuits related to trust, fear, and empathy.
Typical intranasal doses range from 24β48 IU daily in divided applications for behavioral studies. Dose depends on condition and clinical context.
PEG MGF
PEG MGF is a PEGylated variant of Mechano Growth Factor, a splice form of IGF-1 expressed in muscle post-exercise. PEGylation significantly prolongs its half-life, making it more effective for sustained muscle repair and hypertrophy. It has been studied for its role in muscle recovery and hypertrophy in rodent models.
Standard dose: 200 mcg SubQ 2β3 times weekly post-exercise. Cycle duration typically 6β12 weeks.
PE-22-28
PE-22-28 is a short neuropeptide with demonstrated effects in cognitive enhancement, neuroprotection, and mood stabilization. It acts by regulating gene expression and protein synthesis in neurons and has shown positive outcomes in memory, focus, and anxiety models. It is typically administered via subcutaneous injection and has a favorable safety profile in animals.
Standard dose: 400 mcg SQ daily for 4β6 weeks. Range: 200β600 mcg daily. Can be repeated every 2β3 months with a 2β4 week rest period between cycles.
PAL-GHK
PAL-GHK is a lipopeptide derivative of the GHK sequence used in skin rejuvenation. It improves collagen synthesis, reduces signs of aging, and promotes epidermal repair. PAL-GHK is commonly found in cosmetic serums and creams for daily use to restore youthful skin structure and reduce inflammation.
1% topical solution applied once or twice daily to the face or affected area. Continue for 4β12 weeks for visible results.
N-Acetyl Selank Amidate
N-Acetyl Selank Amidate is a nootropic peptide derived from tuftsin and enhanced through N-acetylation for improved stability. It modulates GABA, serotonin, and neurotrophic signaling and has demonstrated powerful anti-anxiety, cognitive-enhancing, and immunomodulatory effects in preclinical and clinical settings. Its intranasal use enables fast CNS action with a high safety margin. It has been investigated in Russian research for immune modulation and neurochemical balance.
Typical dose: 300 mcg intranasally 1β3x daily for 10β14 days per cycle.
Retatrutide
Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed for potent weight loss and metabolic enhancement. It significantly improves body composition, glycemic control, and metabolic rate through synergistic mechanisms affecting appetite regulation, insulin sensitivity, and energy expenditure. Retatrutide is currently under clinical evaluation for obesity and type 2 diabetes management, demonstrating superior efficacy compared to GLP-1 monotherapies like Semaglutide or Tirzepatide. It is currently undergoing Phase II/III clinical trials for obesity and type 2 diabetes.
starts at 4 mg once weekly via subcutaneous injection to assess tolerance, then increases to 8β12 mg weekly based on response, with 12 mg being the upper clinical limit used for fat loss and metabolic benefits.
PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a melanocortin receptor agonist used for sexual enhancement. Unlike PDE5 inhibitors, it works in the brain to increase arousal and libido. It is FDA-approved for female sexual dysfunction and used off-label in men to improve sexual function without affecting vascular systems.
FDA-approved dose (Vyleesi): 1.75 mg SQ ~45 minutes before sexual activity. Max 1 dose per 24 hours, max 8 doses per month. Start at 0.75 mg to assess tolerance. Approved for premenopausal women with HSDD; off-label use in men for erectile dysfunction.
Pinealon
Pinealon is a synthetic tripeptide bioregulator derived from pineal and brain tissue that promotes neuroprotection, memory consolidation, and pineal gland function. It is used in aging, cognitive decline, and circadian rhythm regulation protocols and has demonstrated antioxidant and geroprotective properties in preclinical studies.
5 mcg/kg SubQ daily for 10β20 days per cycle. Repeat 2β3x annually for aging support.
Setmelanotide
Setmelanotide is an FDA- and EMA-approved MC4R (melanocortin 4 receptor) agonist used for the treatment of genetic obesity syndromes such as POMC, LEPR, or PCSK1 deficiency. It acts centrally to restore appetite regulation and reduce hyperphagia, leading to significant weight loss in responsive populations. It is considered one of the first targeted obesity treatments based on melanocortin biology and is being explored for broader metabolic use.
Standard dose: 2 mg SubQ daily, titrated from 1β3 mg based on response and tolerance.
Sermorelin
Sermorelin is a synthetic GHRH analog that stimulates the pituitary to release natural growth hormone, offering a safer and more physiologic alternative to direct GH therapy. Commonly used in adults with GH deficiency, it supports sleep, fat metabolism, recovery, and muscle tone.
Standard dose: 1β2 mcg/kg SQ daily at bedtime (typically 100β300 mcg for most adults). Clinical range: 100β500 mcg/day in research settings. Inject nightly to mimic natural GH rhythm. Cycle: 8β12 weeks on, 4 weeks off.
Semax
Semax is a synthetic ACTH-derived neuropeptide used for its cognitive-enhancing, neuroprotective, and antidepressant effects. Developed in Russia, it modulates neurotransmitters and neurotrophic factors like BDNF. It is used in cognitive decline, stress recovery, stroke rehabilitation, and neuropsychiatric disorders in both animal models and limited human trials.
0.1 mg intranasally 2β3 times daily for 10β14 days per cycle. Repeatable as needed with breaks.
Survodutide
Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed for obesity, MASH (Metabolic Associated Steatohepatitis), and cirrhosis. It promotes significant weight loss, improves liver markers, reduces visceral adiposity, and increases energy expenditure. Human trials report robust reductions in body weight and promising outcomes in liver disease settings. Developed by Boehringer Ingelheim, it is currently in clinical trials.
2.4 mg SubQ once weekly, titrated up from 0.6 mg as tolerated over 4β8 weeks.
SS-31
SS-31 is a mitochondria-targeted antioxidant peptide that is being investigated for its potential in treating diseases linked to mitochondrial dysfunction by reducing oxidative damage. It has been evaluated in animal models and clinical trials for mitochondrial myopathy and metabolic dysfunction.
SQ (FDA-approved as Stegazo): 40 mg once daily for Barth syndrome (patients β₯40 kg). IV (research): 0.05β0.25 mg/kg single infusion in reperfusion injury studies. SQ microdosing: 0.1β1 mg daily reported in off-label longevity protocols.
Snap-8
Snap-8 is a topical cosmetic peptide used to reduce the appearance of fine lines and wrinkles by inhibiting facial muscle contractions. It mimics the effect of Botox but is applied non-invasively, making it ideal for long-term wrinkle control and skin smoothing.
300 mcg applied topically twice daily to affected areas for wrinkle reduction. Effects build over 4β8 weeks.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor (SNDRI) studied for appetite suppression and weight loss. Originally developed for neurodegenerative diseases, it showed significant weight reduction in clinical trials for obesity.
Standard dose: 0.5 mg orally once daily.
Tesamorelin
Tesamorelin is a synthetic analog of GHRH, FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. It stimulates endogenous GH secretion, leading to significant reductions in visceral adipose tissue (VAT) and improvements in body composition. Outside this use, it has been studied in research settings for its effects on growth hormone release, body composition, and metabolic function. In research settings when stacked with Ipamorelin or GHRP-based peptides, it creates sustained GH elevation with improved metabolic outcomes.
Standard dose: 2 mg SubQ daily for 4β6 weeks.
TB-500
TB-500 is a synthetic peptide modeled after Thymosin Beta-4 that promotes tissue regeneration, reduces inflammation, and supports recovery in musculoskeletal injuries. It is often used by researchers and clinicians for its potent actin-binding properties and ability to enhance healing in muscles, tendons, ligaments, and even cardiac tissue.
Standard dose: 2.5 mg SubQ every other day for 4-6 weeks (loading), then 2 mg weekly (maintenance).
Thymosin Alpha-1
Thymosin Alpha-1 (TΞ±1) is a synthetic peptide that enhances the immune system's ability to defend against infections, tumors, and chronic inflammation. It is widely studied for its immunomodulatory effects in cancer therapy, hepatitis, HIV, and other conditions involving immune suppression. Though not FDA-approved in the U.S., it is approved in several countries for adjuvant use in immunocompromised patients.
1.6 mg SubQ 2β3 times per week for 6β12 weeks; long-term maintenance use evaluated in chronic viral and immune disorders.
Thymogen
Thymogen is a thymic-derived short peptide immunomodulator that promotes T-cell activity, immune rebalancing, and resistance to infection. It is widely used in Eastern European protocols to support immune function, particularly in cases of immunodeficiency, chronic infection, or age-related immune decline.
Standard dose: 100 mcg SQ once daily for 10β14 days. Range: 50β300 mcg daily. Repeat cycle every 3β6 months based on immune health status. Pediatric dosing is age-based (not weight-based): ages 1β3: 10β20 mcg; ages 4β6: 20β30 mcg; ages 7β14: 50 mcg; adults: 100 mcg.
Thymalin
Thymalin is a thymic peptide complex known for its potent immunoregulatory effects, supporting T-cell maturation, reducing inflammation, and improving thymic function. It has been investigated for anti-aging, immune optimization, and cancer adjunctive support.
10 mg SubQ daily for 5β10 days, repeated in 2β3 cycles annually. Maintenance protocols use 1β2x weekly for immune health.
VIP
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that modulates immune response, dilates pulmonary vessels, and protects neural tissue. It is being studied for its potential role in treating pulmonary hypertension, COVID-19 respiratory failure, inflammatory and autoimmune disorders, and migraines.
Intranasal (primary route): 50 mcg/spray, 1 spray per nostril 3β4x daily (200β400 mcg total/day). Titrate from 50 mcg 2x daily β 100 mcg 4x daily over 2β4 weeks. SQ (off-label): 100 mcg daily for 4β6 weeks in autoimmune or pulmonary protocols. Used in CIRS, MCAS, and neuroinflammation management.
Vesugen
Vesugen is a synthetic peptide studied for its potential vascular-regulatory effects. It is derived from DNA-regulating peptide complexes and has been evaluated in Russia for its effects on endothelial function and cardiovascular aging.
1 mg SubQ daily for 10β20 days per cycle. Cycles may be repeated every 3β6 months.
Thymosin Beta-4
Thymosin Beta-4 is an endogenous peptide critical for cellular repair and cytoskeletal regulation. It plays a key role in tissue regeneration, inflammation control, and angiogenesis. Distinct from synthetic TB-500 fragments, full-length TB4 is being studied for cardiac recovery, neurological healing, and advanced wound care.
Typical dose: 2 mg SubQ 1β2x weekly for 4β6 weeks. Higher doses used in acute injury or surgery.
IGF-1 LR3
IGF-1 LR3 is a long-acting analog of insulin-like growth factor-1 engineered for enhanced bioavailability and prolonged action. It binds IGF-1 receptors in muscle and bone to stimulate anabolic growth, repair, and recovery. It is studied for its role in cell proliferation, muscle growth, and tissue regeneration in animal models and in vitro systems.
Typical dose: 50 mcg daily SubQ post-workout or in the morning. Cycle 4β6 weeks on, followed by 4 weeks off.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide that provides powerful metabolic regulation for obesity and diabetes. Marketed as Mounjaro and Zepbound, it outperforms GLP-1 monotherapies in weight loss and glycemic control, and is under ongoing investigation for cardiometabolic risk reduction.
Start at 2.5 mg once weekly, titrate every 4 weeks to 5β15 mg as tolerated. Full cycles run 12β24 weeks.
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist peptide used for weight management and glycemic control. It reduces appetite and caloric intake while enhancing insulin secretion and delaying gastric emptying. Available as Ozempic (for diabetes) and Wegovy (for obesity), it is a proven tool in treating metabolic syndrome and aiding fat loss when combined with lifestyle interventions.
0.25 mg weekly for 4 weeks, titrated upward every 2β4 weeks to a maximum of 2.4 mg weekly.
CJC-1295 with DAC
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analog. The DAC modification extends its half-life to 6β8 days by binding to serum albumin, enabling once or twice-weekly dosing instead of the multiple daily injections required by the no-DAC version (Mod GRF 1-29). It produces sustained, non-pulsatile GH elevation.
Standard dose: 600 mcg SQ 1β2x weekly (spaced 3β4 days apart). Range: 300β1000 mcg per injection. Start low (300 mcg) and titrate up based on tolerance. Cycle: 8β12 weeks on, 4 weeks off. The extended half-life (~8 days) from the DAC modification allows weekly dosing vs. the 2β3x daily required for CJC-1295 no DAC.
Adamax
Adamax is a next-generation nootropic peptide and enhanced Semax analog featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration. It upregulates BDNF, enhances TrkB receptor sensitivity, modulates monoamines, and provides neuroprotection against oxidative stress and excitotoxicity.
Standard dose: 300-1000 mcg daily via intranasal spray or injection, administered daily with gradual titration.
HCG (Human Chorionic Gonadotropin)
Human Chorionic Gonadotropin (HCG) is a peptide hormone that mimics luteinizing hormone (LH), stimulating testosterone production from Leydig cells and supporting spermatogenesis. Used clinically for male fertility preservation, testosterone support during replacement therapy, and post-cycle therapy recovery.
Standard dose: 250-500 IU every other day (3x weekly) SubQ for TRT support; 1500-5000 IU 2-3x weekly for PCT.